-
Product Insights
Fred Weber’s Maryland Heights Plant
Fred Weber~s Maryland Heights Plant is a biopower project located in Missouri, United States. The project is owned by Ameren Corp and was developed by Green Companies Inc. The project came online in 2012. Empower your strategies with our Fred Weber~s Maryland Heights Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and...
-
Product Insights
NewFacioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2024
Empower your strategies with our Facioscapulohumeral Muscular Dystrophy (FSHD) – Drugs In Development, 2024 report and make more profitable business decisions. Facioscapulohumeral muscular dystrophy (FSHD) typically manifests with varying degrees of facial, scapular stabilizer, and dorsiflexor muscle weakness. Progression is slow, with about 20% of individuals eventually requiring a wheelchair, though life expectancy remains unaffected. Diagnosis of FSHD1 involves identifying a heterozygous pathogenic contraction of the D4Z4 repeat array on chromosome 4q35 with a chromosome 4 permissive haplotype. FSHD2 diagnosis is...
-
Product Insights
NewSevere Combined Immune Deficiency (SCID) – Drugs In Development, 2024
Empower your strategies with our Severe Combined Immune Deficiency (SCID) – Drugs In Development, 2024 report and make more profitable business decisions. Severe combined immunodeficiency (SCID) is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. Infants with SCID appear healthy at birth but are highly susceptible to severe infections. The condition is fatal, usually within the first year or two of life, unless infants receive immune-restoring treatments such...
-
Product Insights
NewPrimary Immune Deficiency (PID) – Drugs In Development, 2024
Empower your strategies with our Primary Immune Deficiency (PID) – Drugs In Development, 2024 report and make more profitable business decisions. Primary immune deficiency (PID) is defined as weakened immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, and digestive problems such as cramping, loss of appetite, nausea, and diarrhea. The Primary Immune Deficiency (PID) drugs in development market research report...
-
Product Insights
NewChronic Myelomonocytic Leukemia (CMML) – Drugs In Development, 2024
Empower your strategies with our Chronic Myelomonocytic Leukemia (CMML) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic Myelomonocytic Leukemia (CMML) is a type of rare blood cancer that combines features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). It primarily affects the bone marrow and blood cells, resulting in the overproduction of abnormal monocytes (a type of white blood cell) and other blood cells. CMML is characterized by an increased number of monocytes in the...
-
Product Insights
NewMuscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The Muscular Dystrophy drugs in development market research report provide comprehensive information on...
-
Product Insights
NewLymphocryptovirus Infections – Drugs In Development, 2024
Empower your strategies with our Lymphocryptovirus Infections – Drugs In Development, 2024 report and make more profitable business decisions. Lymphocryptovirus infections are caused by a genus of herpesviruses that infect humans and other primates. The most well-known lymphocryptovirus is the Epstein-Barr virus (EBV), which can cause mononucleosis, lymphoma, and nasopharyngeal carcinoma in humans. Lymphocryptovirus infections are usually latent, meaning that the virus remains dormant in the host cells until it is reactivated by stress or immune suppression. Lymphocryptovirus infections can be...
-
Product Insights
NewNeuropathy – Drugs In Development, 2024
Empower your strategies with our Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Neuropathy, also known as peripheral neuropathy, refers to a condition involving damage or dysfunction of the nerves outside the brain and spinal cord (peripheral nerves). This condition can affect a single nerve or multiple nerves and can result from various causes. Common types include diabetic neuropathy, resulting from diabetes-related nerve damage due to high blood sugar levels; peripheral neuropathy, often due to conditions...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...